Clinical Trials Browser

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

NCT01415011 2019-01-15

TIMELY

Phase 2 Completed

39 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02488694 2018-01-09

MARBLE

Phase 2 Terminated

4 enrolled

Thoracic

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT02876081 2017-09-11

THEN

Phase 2 Withdrawn

Thoracic

Small Cell Lung Carcinoma

NCT00525148 2016-09-16

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase 2 Completed

129 enrolled 18 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02470065 2016-01-22

REMNANT

Phase 2 Suspended

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00711594 2015-01-15

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Phase 2 Completed

74 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00730925 2014-03-26

Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients

Phase 2 Completed

41 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01003899 2013-12-31

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Phase 2 Completed

43 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01480141 2013-03-26

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Thoracic

Lung Neoplasms

Clinical Trials

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Afatinib in NSCLC With HER2 Mutation

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Afatinib With CT and RT for EGFR-Mutant NSCLC

NSCLC

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

DARWIN1

AFACET

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

TRUMP

ACE-Lung

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

LiquidLung-A

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Trans-MARBLE

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

TIMELY

MARBLE

THEN

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

REMNANT

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)